Gershenson D M, Kavanagh J J, Copeland L J, Edwards C L, Stringer C A, Wharton J T
J Clin Oncol. 1987 Apr;5(4):618-21. doi: 10.1200/JCO.1987.5.4.618.
Eighteen patients with metastatic mixed mesodermal sarcoma of the uterus received cisplatin therapy at the University of Texas (UT) M.D. Anderson Hospital and Tumor Institute at Houston. The dose of cisplatin varied from 75 mg/m2 to 100 mg/m2. Previous therapy included surgery in 11 patients, radiotherapy in two patients, and surgery plus radiotherapy in four patients. One patient had no prior therapy. Seven patients had also received prior chemotherapy with doxorubicin. Of 12 patients with measurable disease, one (8%) had a complete response and four (33%) had a partial response for an overall response rate of 42%. The median progression-free survival of patients treated with cisplatin as first- and second-line therapy was 4.5 and 5.5 months, respectively. Cisplatin demonstrated moderate activity with mild toxicity in this group of patients with metastatic mixed mesodermal uterine sarcomas. Further studies including cisplatin-containing combination regimens seem to be warranted.
18例子宫转移性混合性中胚层肉瘤患者在位于休斯敦的德克萨斯大学（UT）MD安德森癌症中心接受了顺铂治疗。顺铂剂量从75mg/m²至100mg/m²不等。既往治疗包括11例患者接受过手术，2例患者接受过放疗，4例患者接受过手术加放疗。1例患者未接受过既往治疗。7例患者还曾接受过阿霉素化疗。在12例有可测量病灶的患者中，1例（8%）完全缓解，4例（33%）部分缓解，总缓解率为42%。接受顺铂一线和二线治疗的患者无进展生存期的中位数分别为4.5个月和5.5个月。顺铂在这组转移性子宫混合性中胚层肉瘤患者中显示出中度活性且毒性较轻。似乎有必要进行包括含顺铂联合方案在内的进一步研究。
